Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by October 14, 2025 [2][4]. Group 1: Company Overview - Unicycive Therapeutics, Inc. is a company listed on NASDAQ under the ticker UNCY [2]. - The firm Faruqi & Faruqi has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Allegations and Stock Performance - The complaint against Unicycive alleges that the company and its executives made false or misleading statements regarding their readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of their OLC NDA [4]. - Following a press release on June 10, 2025, regarding FDA deficiencies, Unicycive's stock price dropped by $3.68 per share, a decline of 40.89%, closing at $5.32 per share [5]. - On June 30, 2025, after the FDA issued a Complete Response Letter citing the same deficiencies, the stock fell by $2.03 per share, or 29.85%, closing at $4.77 per share [6]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $50,000 between March 29, 2024, and June 27, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the ability to direct and oversee the litigation [7].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit due to allegations of materially false and misleading statements made by the company during the specified class period [1]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from May 7, 2025, to August 5, 2025, LifeMD's management overstated the company's competitive position [1]. - It is claimed that the company was reckless in raising its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [1]. - As a result, the statements made by the defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [1]. Class Action Details - Shareholders who purchased shares of LifeMD during the class period are encouraged to register for the class action, with a deadline set for October 25, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that led to artificial inflation of stock prices [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PubMatic, Inc. regarding a class action lawsuit due to allegations of misleading statements and undisclosed information that negatively impacted the company's stock value during a specified period [1]. Group 1: Allegations and Impact - The complaint alleges that during the class period from February 27, 2025, to August 11, 2025, PubMatic's defendants made materially false and misleading statements [1]. - A significant demand side platform buyer shifted clients to a new platform, leading to a reduction in ad spend and revenue for PubMatic [1]. - The misleading statements about the company's business and prospects lacked a reasonable basis due to the aforementioned issues [1]. Group 2: Class Action Details - Shareholders who purchased shares of PUBM during the specified class period are encouraged to register for the class action, with a deadline of October 20, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3].

Core Points - The Gross Law Firm has issued a notice to shareholders of Semler Scientific, Inc. regarding a class action lawsuit for alleged misleading statements and failure to disclose a material investigation by the U.S. Department of Justice [1][2] - The class period for the allegations spans from March 10, 2021, to April 15, 2025, with a deadline for shareholders to register for the class action by October 28, 2025 [2] - The firm emphasizes its commitment to protecting investors' rights and ensuring companies adhere to responsible business practices [3] Summary by Sections Allegations - The complaint alleges that Semler Scientific did not disclose a material investigation by the U.S. Department of Justice related to violations of the False Claims Act, while discussing potential violations in hypothetical terms [1] - As a result, the defendants' public statements were materially false and/or misleading throughout the relevant period [1] Class Action Details - Shareholders who purchased shares of SMLR during the specified class period are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment [1] - Registration for the class action is free, and participants will receive updates through portfolio monitoring software [2] Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors from deceit, fraud, and illegal business practices [3] - The firm aims to recover losses incurred by investors due to false or misleading statements that led to artificial inflation of stock prices [3]

Core Viewpoint - Fly-E Group, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety of its lithium batteries, which negatively impacted its electric vehicle sales and revenue projections [1]. Summary by Relevant Sections Allegations - The complaint claims that Fly-E Group made overly positive statements while concealing material adverse facts about the safety of its lithium batteries, leading to a significant decline in E-vehicle sales revenue [1]. - On August 14, 2025, Fly-E reported a 32% decrease in net revenues, primarily due to a drop in total units sold, which was attributed to recent lithium-battery accidents involving E-Bikes and E-Scooters [1]. Stock Price Impact - Following the revelation of the financial difficulties, Fly-E's stock price plummeted from $7.76 per share on August 14, 2025, to $1.00 per share on August 15, 2025, marking an approximate decline of 87% in just one day [1]. Class Action Details - Shareholders who purchased shares during the class period from July 15, 2025, to August 14, 2025, are encouraged to register for the class action, with a lead plaintiff deadline set for November 10, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Spectrum Pharmaceuticals, Inc. during the specified class period of the upcoming lead plaintiff deadline on September 24, 2025 [1]. Group 1: Class Action Details - Investors who bought Spectrum Pharmaceuticals common stock between May 12, 2022, and September 22, 2022, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][5]. - The lawsuit alleges that Spectrum made false or misleading statements regarding its PINNACLE Study related to the drug poziotinib, which impacted investors when the true details were revealed [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. Group 3: Class Certification Status - No class has been certified yet, meaning investors are not represented by counsel unless they retain one, and they can choose to remain absent from the class [6].

Core Viewpoint - Investors in C3.ai, Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements regarding the company's growth and the health of its CEO [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit claims that from February 26, 2025, to August 8, 2025, C3.ai's management failed to disclose critical information, including the over-reliance on the CEO's health and effectiveness [2]. - Allegations include that the optimistic reports on growth, earnings potential, and margins were not reflective of the actual situation, as the CEO had not sufficiently recovered to fulfill his role [2]. Participation Information - Investors who suffered losses related to C3.ai are encouraged to participate in the lawsuit before the lead plaintiff deadline of October 21, 2025 [2]. - Interested parties can contact The Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

Group 1 - The Rosen Law Firm is reminding purchasers of Tronox Holdings plc common stock from February 12, 2025, to July 30, 2025, about the lead plaintiff deadline on November 3, 2025 [1][2] - Investors who purchased Tronox common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][3] - A class action lawsuit has already been filed against Tronox, alleging that the company provided misleading statements about its commercial division and failed to accurately forecast demand for its products, leading to investor damages [5] Group 2 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4] - The firm has been recognized for its performance in securities class action settlements, including a record settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4] - Investors are informed that no class has been certified yet, and they have the option to select their counsel or remain absent from the class [7]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Flywire Corporation regarding a class action lawsuit, highlighting allegations of misleading statements related to the company's revenue growth and the impact of permit and visa restrictions on its business [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from February 28, 2024, to February 25, 2025 [2]. - Allegations include that Flywire's revenue growth was overstated and that the negative impact of permit and visa-related restrictions was understated, leading to materially false and misleading public statements [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 23, 2025, to potentially be appointed as lead plaintiffs [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [4]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that inflated stock prices [4].

Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [2][4]. Group 1: Allegations and Impact - The lawsuit claims that Capricor provided investors with overly positive information about its ability to obtain a Biologics License Application (BLA) from the FDA while concealing adverse facts about the safety and efficacy data from its Phase 2 HOPE-2 trial [2]. - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness and the need for additional clinical data, Capricor's stock price fell from $11.40 to $7.64 per share [2]. Group 2: Class Action Details - The class period for the lawsuit is defined as October 9, 2024, to July 10, 2025, and shareholders are encouraged to register for potential lead plaintiff appointment [2][3]. - The deadline for shareholders to seek lead plaintiff status is September 15, 2025, and there is no cost or obligation to participate in the case [3]. Group 3: Legal Representation - The Gross Law Firm, a nationally recognized class action law firm, is representing the shareholders and aims to protect investors' rights against deceit and fraud [4]. - The firm emphasizes its commitment to ensuring responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].